Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE for rhabdomyosarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Sep 2023: Trial registered, NCT06023641
  2. 13 Mar 2024: Trial started, NCT06023641

The trials

NCT06023641: Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

State
Under way
Phase
Phase 2
People
135 planned
Started
13 Mar 2024
Primary completion
Oct 2034
Arms
Intermediate-risk
Results
None posted
  1. 5 Sep 2023: Trial registered
  2. 13 Mar 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.